SCHEMBL7149398

SCHEMBL7149398

O=C(O)CN1C(=O)C(=Cc2ccc(OCCCc3ccccc3)cc2OCc2ccc(Cl)cc2)SC1=S

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 6/20 0.73
KMT2A Q03164 6/20 0.73
MEN1 O00255 5/20 0.73
PLA2G1B P04054 1/20 0.65
DNMT1 P26358 1/20 0.65
GFER P55789 1/20 0.65
ATG4B Q9Y4P1 1/20 0.65
AKR1B1 P15121 7/20 0.65
PTPN1 P18031 5/20 0.61
PTPN2 P17706 1/20 0.61
USP2 O75604 1/20 0.59
NCOA1 Q15788 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
NCOA3 Q9Y6Q9 1/20 0.59
MMP3 P08254 1/20 0.58
MMP13 P45452 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149394 1.00 POLB (0.73) POLBKMT2AMEN1PLA2G1BDNMT1
SCHEMBL7143955 0.95 AKR1B1 (0.71) POLBKMT2AMEN1GFERAKR1B1
SCHEMBL7143950 0.95 AKR1B1 (0.71) POLBKMT2AMEN1GFERAKR1B1
SCHEMBL7143689 0.94 MEN1 (0.74) POLBKMT2AMEN1PLA2G1BDNMT1
SCHEMBL7143685 0.94 MEN1 (0.74) POLBKMT2AMEN1PLA2G1BDNMT1
SCHEMBL7146822 0.94 POLB (0.66) POLBKMT2AMEN1PLA2G1BDNMT1
SCHEMBL7146825 0.94 POLB (0.66) POLBKMT2AMEN1PLA2G1BDNMT1
SCHEMBL7399985 0.91 POLB (0.78) POLBKMT2AMEN1PLA2G1BDNMT1
SCHEMBL7145580 0.91 POLB (0.78) POLBKMT2AMEN1PLA2G1BDNMT1
SCHEMBL7144830 0.91 AKR1B1 (0.75) POLBKMT2AMEN1GFERAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506755-B2 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis HOFFMANN-LA ROCHE INC. 2003-01-14 US disclosed
US-20020037901-A1 Thiazolidinecarboxyl acids HOFFMANN-LA ROCHE INC. 2002-03-28 US disclosed
EP-1189894-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-03-27 EP disclosed
WO-2001057006-A1 THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037901-A1 Thiazolidinecarboxyl acids TPMT, NAT1, THRA POLB 3974/4885KMT2A 1605/4885MEN1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.